EP0202758A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Hybridization method and probes therefor
Assignee: Syngenta Ltd
•
Filing: 1986-04-14
•
Granted: —
•
Expires: 2006-04-14
Abstract
Abstract A method for discriminating between two complementary nucleotide sequences differing by as little as 1-3 nucleotides is described in which an oligonucleotide signalling complex probe is used, which probe comprises a single stranded oligonucleotide of 8 to 30 nucleotide units having covalently attached thereto, at a sterically tolerant site, a residue capable of producing a non-radioisotopic signal and having a molecular weight of at least 100 daltons. Oligonucleotide signalling complex probes and diagnostic kits for use in such a method are described and claimed.
Inventors
- 👤 Francis Joseph Carr
- 👤 Michael Derek Edge
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 20:36
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6813; C12Q1/6827; C12Q1/6816
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
150 words
A method for discriminating between two complementary nucleotide sequences differing by as little as 13 nucleotides which comporises:- (a) under conditions which promote or favour hybridisation between two complementary oligonucleotide strands, contacting the nucleotide sequence (after appropriate treatment to render it single stranded) to be identified or determined with an oligonucleotide-signalling complex probe comprising a single stranded oligonucleotide of 8 to 30 nucleotide units in length and having covalently attached thereto, at a sterically tolerant site, a residue having a molecular weight of at least 1,000 daltons, which residue is capable of producing a non-radioisotopic signal, the oligonucleotide in the oligonucleotide-signal complex having a defined sequence which is complementary to a sequence to be identified or determined but which is not complementary to an alternative sequence; (b) separating the probe:test nucleic acid hybrid from the unhybridized probe; and (c) producing or observing the signal resulting from the hybridised oligonucleotide-signalling complex.
Claim 2
Independent Claim
150 words
A method for discriminating between two complementary nucleotide sequences differing by as little as 13 nucleotides which comporises:- (a) under conditions which promote or favour hybridisation between two complementary oligonucleotide strands, contacting the nucleotide sequence (after appropriate treatment to render it single stranded) to be identified or determined with an oligonucleotide-signalling complex probe comprising a single stranded oligonucleotide of 8 to 30 nucleotide units in length and having covalently attached thereto, at a sterically tolerant site, a residue having a molecular weight of at least 1,000 daltons, which residue is capable of producing a non-radioisotopic signal, the oligonucleotide in the oligonucleotide-signal complex having a defined sequence which is complementary to a sequence to be identified or determined but which is not complementary to an alternative sequence; (b) separating the probe:test nucleic acid hybrid from the unhybridized probe; and (c) producing or observing the signal resulting from the hybridised oligonucleotide-signalling complex.
Claim 3
Dependent Claim
19 words
A method as claimed in claim 1 wherein the residue has a molecular weight of at least 5000 daltons.
Claim 4
Dependent Claim
19 words
A method as claimed in claim 2 wherein the residue has a molecular weight of at least 20,000 .daltons.
Claim 5
Independent Claim
27 words
A method as claimed in any one of the preceding claims effective to discriminate between two complementary nucleotide sequences differing by as little as a single nucleotide.
Claim 6
Independent Claim
26 words
A method as claimed in any one of the preceding claims wherein the residue which is capable of producing a non-radioisotopic signal comprises a proteinaceous moiety.
Claim 7
Independent Claim
68 words
A method as claimed in any one of the preceding claims wherein the oligonucleotide signalling complex probe comprises a single stranded oligonucleotide sequence having a detection system covalently attached thereto via a spacer group, said detection system comprising a system for producing an enzymatically activated production of colour change, the system being linked to the spacer group by a direct covalent link or by a specific binding pair.
Claim 8
Dependent Claim
96 words
An oligonucleotide signalling complex which comprises a single stranded oligonucleotide of 8 to 30 nucleotide units in length having covalently attached thereto at a sterically tolerant site, via a spacer group, either a residue comprising a specific binding pair optionally carrying an enzyme label, said residue having a molecular weight of at least 1000 daltons or a residue comprising an enzyme label, with the proviso that where an enzyme label is linked to the oligonucleotide via a spacer group, the linkage of the spacer group to the oligonucleotide is via the terminal base, sugar or phosphate.
Claim 9
Dependent Claim
96 words
An oligonucleotide signalling complex which comprises a single stranded oligonucleotide of 8 to 30 nucleotide units in length having covalently attached thereto at a sterically tolerant site, via a spacer group, either a residue comprising a specific binding pair optionally carrying an enzyme label, said residue having a molecular weight of at least 1000 daltons or a residue comprising an enzyme label, with the proviso that where an enzyme label is linked to the oligonucleotide via a spacer group, the linkage of the spacer group to the oligonucleotide is via the terminal base, sugar or phosphate.
Claim 10
Dependent Claim
31 words
An oligonucleotide signalling complex as claimed in claim 7 wherein the oligonucleotide has a sequence complementary to a nucleotide sequence associated with a disease state or with the corresponding normal sequence.
Claim 11
Dependent Claim
109 words
A diagnostic kit for discriminating between two complementary nucleotide sequences differing by as little as a single nucleotide,-one of the said-sequences being associated with disease state and the other of said sequences being the corresponding normal sequence, which kit comprises at least one oligonucleotide-signalling complex probe comprising a single stranded oligonucleotide of 8 to 30 nucleotide unis in length, said oligonucleotide having a sequence complementary to a sequence associated with a disease state or the corresponding normal sequence, said oligonucleotide having covalently attached thereto, at a sterically tolerant site, a residue having a molecular weight of at least 1000 daltons, which residue is capable of producing a non-radioisotopic signal.
Claim 12
Dependent Claim
109 words
A diagnostic kit for discriminating between two complementary nucleotide sequences differing by as little as a single nucleotide,-one of the said-sequences being associated with disease state and the other of said sequences being the corresponding normal sequence, which kit comprises at least one oligonucleotide-signalling complex probe comprising a single stranded oligonucleotide of 8 to 30 nucleotide unis in length, said oligonucleotide having a sequence complementary to a sequence associated with a disease state or the corresponding normal sequence, said oligonucleotide having covalently attached thereto, at a sterically tolerant site, a residue having a molecular weight of at least 1000 daltons, which residue is capable of producing a non-radioisotopic signal.
Claim 13
Dependent Claim
72 words
A diagnostic kit as claimed in claim 9 which comprises 1) at least one oligonucleotide signalling complex probe comprising a single stranded oligonucleotide having a sequence complementary to a sequence associated with a disease state and 2) at least one oligonucleotide signalling complex probe comprising a single stranded oligonucleotide having a sequence complementary to the corresponding normal sequence which would be present in a human not subject to the said disease state.
References Cited (Backward Citations)
GB2019408A
Cited
EP0117440A1
Cited
EP0119448A1
Cited
WO1984003285A1
Cited
WO1984003520A1
Cited
EP0138357A2
Cited
FR2556726A1
Cited
EP0154505A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.